Posts by Christopher
Jeff Galvin Explains AGT’s Innovative Approach to HIV on Bio Blast
Jeff Galvin, the CEO of American Gene Technologies and it’s HIV division Addimmune discusses his career path from working in Silicon Valley to becoming involved in the biotech sector. He initially discovered computers in his junior high school and was fascinated by their potential to improve lives. This passion for technology led him to teach…
Read MoreMarcus Conant, MD, on More Research Needed With HIV Therapies
Recent research published in Frontiers in Medicine highlights promising results from a gene therapy trial for HIV. AGT103-T, developed by our subsidiary Addimmune, was well-tolerated and demonstrated viral control in people with HIV when combined with multiple treatment interruptions. This innovative approach offers hope for those living with HIV, especially considering the unmet need for…
Read MoreMultiple Treatment Interruptions and Protecting HIV-Specific CD4 T Cells Enable Durable CD8 T Cell Response and Viral Control
American Gene Technologies and its HIV division Addimmune conducted A study investigating the impact of AGT103-T treatment upon analytical treatment interruptions (ATIs) in HIV patients. AGT103-T, a cell and gene therapy product, was evaluated for its ability to enable durable CD8 T cell response and viral control. The study involved multiple ATIs where patients suspended…
Read MoreA Lifetime Fighting HIV: Dr. Marcus Conant Shares Addimmune’s Vision for a Cell Therapy Cure
In this episode of Cell & Gene: The Podcast, Dr. Marcus Conant, a seasoned HIV expert and Chief Medical Officer at Addimmune, delves into the company’s innovative cell therapy, AGT103-T. With a career dedicated to HIV treatment and advocacy, Dr. Conant explains how this therapy could revolutionize HIV care by offering broad protection against the…
Read MoreAddimmune’s Dr. Marcus Conant, MD on CGTLive Discusses Gene Therapy for HIV Suppression
American Gene Technologies’ HIV division, Addimmune, is at the forefront of developing a gene therapy for HIV suppression called AGT103-T. This promising therapy utilizes lentivirus to deliver micro RNAs that prevent HIV from entering cells. The research is being led by Dr. Jerome Marcus, a world-renowned HIV/AIDS expert. Early phase 1 trials have shown encouraging…
Read MoreAddimmune: Helping Power the Gene and Cell Therapy Revolution in Montgomery County
Montgomery County, Maryland, is a dynamic hub for gene and cell therapy innovation, and American Gene Technologies (AGT) and its HIV division, Addimmune, are at the forefront of this medical revolution. AGT’s CEO, Jeff Galvin, recognizes Maryland’s exceptional support for biotechnology and the state’s deep expertise in viral vector technologies, making it an ideal location…
Read MoreTransaction Trends 2023: Things Are Starting to Look Up
Following the excesses of 2020 and 2021, which produced some of the most exuberant life sciences activity in decades, activity was anemic for both merger and acquisitions (M&A) and initial public offerings (IPOs). Rising interest rates, prompted by inflationary pressures, rose from a low in spring of 2021 to a recent peak in October 2023.…
Read MoreEmpowered Patient: The Potential of a Functional Cure for HIV with Dr. Marc Conant of Addimmune
In an enlightening episode of the Empowered Patient Podcast, Dr. Marc Conant, Chief Medical Officer at Addimmune, delves into the innovative realm of HIV care, focusing on the development of a functional cure through gene and cell therapy. Addimmune is at the forefront of this revolutionary approach, aiming to modify patients’ cells to empower their…
Read MoreBringing hope to those living with HIV: Addimmune’s promising potential treatment in development
1 In 300 People In The U.S. Is Living With HIV. That’s Not Okay With Jeff Galvin. This in-depth article takes you on a fascinating journey through the world of HIV research and explores a groundbreaking company leading the charge toward a cure. It delves into the history of HIV treatment, highlighting the remarkable progress…
Read More